Autopsy report · NCT00491075

Pemetrexed Plus Gemcitabine in Renal Cell Cancer

“Closed early for poor accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months after it had already started.
• Ran for about 5 years 9 months before it stopped.
• 16 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Renal Cell Carcinoma

Interventions

Pemetrexed; Gemcitabine

Participants

16

Sites

1

Countries

United States

Trials that died the same way

• Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL
  “Closed early due to poor accrual.” (94% match in meaning)
• Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma
  “Closed early due to low accrual.” (93% match in meaning)
• Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning
  “Closed early due to slow accrual.” (88% match in meaning)
• Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease
  “Closed due to low accrual” (74% match in meaning)
• Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
  “Closed prematurely because the accrual was not achieved” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.